The Final Step Out The Biotech IPO Window Is A Small One
This article was originally published in Start Up
Executive Summary
Ultimately, more than a dozen biotechs are expected to go public in 2012. But the comeback is being muted thanks to unremarkable step-ups in valuation between final venture rounds and IPOs. Earlier rounds, however, show signs of better step-ups.